M&A Speculation

3 articles in this category

Stock Weather AIBiotechnologyM&A Speculation

Revolution Medicines – 2026-01-26 - increase Confidence 7/10

Negative free cash flow contrasts with Merck's terminated $32B acquisition talks and upcoming 2026 clinical catalysts, signaling near-term upside potential.

Jan 26, 2026RVMD

Stock Weather AIBiotechnologyM&A Speculation

NovaBay Pharmaceuticals – 2026-01-09 - increase Confidence 6/10

Negative free cash flow contrasts with potential acquisition catalyst, driving short-term upside in speculative momentum.

Jan 9, 2026NBY

Stock Weather AIBiotechnologyM&A Speculation

Jyong Biotech Ltd. – 2025-12-02 - increase Confidence 6/10

Negative free cash flow contrasts with strategic LOI news for MCS-2 in South Korea, creating near-term speculative upside.

Dec 2, 2025MENS